Form 4: BioLife Solutions Director Rachel Ellingson Reports Acquisition of Common Stock

Director Rachel Ellingson reports acquiring 6,876 shares of BioLife Solutions common stock on March 18, 2025, bringing her total direct holdings to 49,825 shares.

Summary

• On March 18, 2025, Rachel Ellingson, a director of BioLife Solutions Inc., acquired 6,876 shares of common stock.
• The acquisition was a direct purchase.
• Following the transaction, Ellingson directly owns 49,825 shares of BioLife Solutions Inc.
• The restricted stock was granted under the BioLife Solutions 2023 Performance Incentive Plan and fully vests on January 2, 2026, which is the first anniversary of the measurement date of January 2, 2025.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine disclosure of stock acquisition by a director. While insider buying can be seen as positive, this is a relatively small transaction and part of a pre-existing incentive plan.

Positives

• A director increasing their holdings could be seen as a positive signal about their confidence in the company's future.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders.

Stakeholder Impact

• The transaction could have a minor positive impact on shareholder sentiment.

Key Dates

Keywords

BioLife Solutions, BLFS, Rachel Ellingson, Form 4, Beneficial Ownership, Director, Stock Acquisition, Restricted Stock, 2023 Performance Incentive Plan